Carlo Alessandria

TL;DR: Diagnostic criteria for ACLF was established and showed that it is distinct from AD, based not only on the presence of organ failure(s) and high mortality rate but also on age, precipitating events, and systemic inflammation.

TL;DR: The CLIF-C ACLFs is a clinically relevant, validated scoring system that can be used sequentially to stratify the risk of mortality in ACLF patients and is superior to the MELDs and MELD-Nas in predicting mortality.

TL;DR: Patients with AD without ACLF showed very high baseline levels of inflammatory cytokines, HNA2, PRC, and PCC, and the strength of association of ACLF with SI was higher than with SCD, supporting SI as the primary driver of ACLf in cirrhosis.

TL;DR: Assessment of ACLF patients at 3‐7 days of the syndrome provides a tool to define the emergency of LT and a rational basis for intensive care discontinuation owing to futility.

TL;DR: Long-term HA administration prolongs overall survival and might act as a disease modifying treatment in patients with decompensated cirrhosis in this trial.